SEEBRI BREEZHALER (GLYCOPYRRONIUM) - HIGH AFFINITY INHALED ANTICHOLINERGIC FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Abstract

Glikopironium bromide (glycopyrronium) - the new, high affinity, inhaled, long acting anticholinergic bronchodilator started to use in clinical practice. It is dry-powder, once-daily used medication, approved for the treatment of chronic obstructive pulmonary disease (COPD). Glycopyrronium has rapid onset of action – its bronchodilation effect starts within 5 minutes after the first dose inhalation. Bronchodilation effect of glycopyrronium sustains 24-hours and does not diminish using this medication continually for a long time. Glycopyrronium is effective, safe and well tolerated as the only known long-acting anticholinergic, tiotropium bromide glycopyrronium significantly reduced moderate and severe COPD exacerbation rate and the use of short acting rescue medication. Once daily used glycopyrronium (Seebri Breezhaler) could be an alternative choice to currently reimbursed long acting anticholinergic tiotropium, for the treatment of patients with COPD.